VISIONIX INTERNATIONAL acquired by REVENIO GROUP CORPORATION
Context
The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market. The strategic rationale for this transaction centers on a "portfolio-convergence" play, merging the target's industry-leading technical operational depth in refraction and finishing with the group’s established leadership in tonometry and imaging. This fusion effectively creates a specialized powerhouse in the ophthalmic arena, providing the organization with the scientific talent and technological hardware required to address the increasing complexity of diagnostic and optical retail workflows. The operation allows the group to execute a definitive structural expansion of its total addressable market, specifically targeting high-growth segments such as Optical Coherence Tomography (OCT). By incorporating the target's innovative product suite, the organization can now provide a more robust and integrated solution set for professionals across optometry, retail, and ophthalmology.
VISIONIX INTERNATIONAL, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Visionix International operates as a premier technology organization dedicated to the engineering and distribution of advanced ophthalmic diagnostic and optical technologies. The entity’s business model is centered on a proprietary framework of high-performance refraction, screening, and lens finishing solutions designed to optimize clinical and retail workflows. Its value proposition is anchored in technical operational depth, providing integrated hardware and software platforms that facilitate precise vision correction and early disease detection. Strategically, the firm focuses on the deployment of automated diagnostic systems and telehealth-enabled solutions to address the evolving needs of the optical retail and optometry segments. By maintaining a specialized focus on technical innovation and industrialized quality standards, the organization ensures a vital role in the structural advancement of vision care accessibility.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | BRIDGEPOINT | OBAGI MEDICAL | UNITED STATES | Generics / Labs |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Medical Devices |
| 04/2026 | FOR TALENTS / UI INVESTISSEMENT / GENEO | NEFTYS PHARMA | FRANCE | Animal Health |
| 04/2026 | OURY MEDICAL | CÉFIMÉCA | FRANCE | Implants & Prosthetics |
| 04/2026 | Gilead Sciences | Arcellx | UNITED STATES | R&D Biotech |
| 04/2026 | FINE FOODS & PHARMACEUTICALS | SOFAR | ITALY | CDMO |
| 04/2026 | AMERICAN INDUSTRIAL PARTNERS AIP | AVANOS MEDICAL | UNITED STATES | Medical Consumables |
| 04/2026 | RANTUM CAPITAL | TONTARRA MEDIZINTECHNIK | GERMANY | Medical Devices |
| 04/2026 | UCB | NEURONA THERAPEUTICS | UNITED STATES | R&D Biotech |
| 04/2026 | HALMA | SURGISTAR | UNITED STATES | Medical Devices |
REFERENCES
Valuation range: EV 300M - 700M EUR
Revenue range: 100M - 200M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VISIONIX INTERNATIONAL by REVENIO GROUP CORPORATION are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: visionix international
Acquirer: revenio group corporation